DK1159003T3 - Anti-tnfalfa-antistoffer til terapi af steroid-resistent astma - Google Patents

Anti-tnfalfa-antistoffer til terapi af steroid-resistent astma

Info

Publication number
DK1159003T3
DK1159003T3 DK00912065.0T DK00912065T DK1159003T3 DK 1159003 T3 DK1159003 T3 DK 1159003T3 DK 00912065 T DK00912065 T DK 00912065T DK 1159003 T3 DK1159003 T3 DK 1159003T3
Authority
DK
Denmark
Prior art keywords
treatment
tnfalfa
steroid
antibodies
resistant asthma
Prior art date
Application number
DK00912065.0T
Other languages
English (en)
Inventor
George Treacy
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Application granted granted Critical
Publication of DK1159003T3 publication Critical patent/DK1159003T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
DK00912065.0T 1999-03-02 2000-03-01 Anti-tnfalfa-antistoffer til terapi af steroid-resistent astma DK1159003T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26095399A 1999-03-02 1999-03-02
US46569199A 1999-12-17 1999-12-17
PCT/US2000/005163 WO2000051637A1 (en) 1999-03-02 2000-03-01 ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA

Publications (1)

Publication Number Publication Date
DK1159003T3 true DK1159003T3 (da) 2011-02-07

Family

ID=26948290

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00912065.0T DK1159003T3 (da) 1999-03-02 2000-03-01 Anti-tnfalfa-antistoffer til terapi af steroid-resistent astma

Country Status (10)

Country Link
US (3) US20010021381A1 (da)
EP (1) EP1159003B1 (da)
JP (2) JP2002538170A (da)
AT (1) ATE488250T1 (da)
AU (1) AU756677B2 (da)
CA (1) CA2364026C (da)
DE (1) DE60045240D1 (da)
DK (1) DK1159003T3 (da)
PT (1) PT1159003E (da)
WO (1) WO2000051637A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
JP2006517214A (ja) * 2003-02-11 2006-07-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な抗コリン作用剤とＴＮＦα合成又は作用阻害剤に基づく新規な医薬組成物
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
TWI414531B (zh) * 2006-10-12 2013-11-11 Genentech Inc 淋巴毒素α之抗體
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
EP2173380A4 (en) * 2007-07-13 2011-08-31 Abbott Biotech Ltd METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER
ES2616728T3 (es) 2008-05-23 2017-06-14 Siwa Corporation Procedimientos y composiciones para facilitar la regeneración
EP2676137B1 (en) * 2011-02-17 2014-12-31 Nestec S.A. Assays for detecting autoantibodies to anti-tnf drugs
AU2015318036B2 (en) * 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
CA3021150C (en) 2016-02-19 2023-02-07 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN115804821A (zh) * 2022-12-19 2023-03-17 新疆维吾尔药业有限责任公司 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822776A (en) * 1981-09-08 1989-04-18 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US6419927B1 (en) * 1981-09-08 2002-07-16 Anthony Cerami Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US6309640B1 (en) * 1981-09-08 2001-10-30 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP2647427B2 (ja) * 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US5360716A (en) * 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
DE69231828T3 (de) * 1991-03-18 2008-06-19 New York University Spezifisch gegen menschlichen Tumornekrosefaktor gerichtete monoklonale und chimäre Antikörper
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
DE4139733A1 (de) * 1991-11-28 1993-06-03 Schering Ag Carbacyclinderivate als mittel zur behandlung von krankheitsbildern, die zum atopie-kreis gehoeren
ATE155043T1 (de) * 1992-10-08 1997-07-15 Kennedy Inst Of Rheumatology Behandlung von autoimmun- und entzundungskrankheiten
CA2147180A1 (en) * 1992-10-15 1994-04-28 Gokhan S. Hotamisligil Treatment of insulin resistance in obesity linked type ii diabetes using antagonists to tnf-.alpha. function
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
ATE204299T1 (de) * 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
SE9302490D0 (sv) * 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
GB9403909D0 (en) * 1994-03-01 1994-04-20 Erba Carlo Spa Ureido derivatives of naphthalenephosphonic acids and process for their preparation
NZ536216A (en) * 1996-02-09 2006-08-31 Abbott Biotech Ltd Use of an isolated antibody D2E7 for the treatment of a disorder in which TNF(alpha) activity is detrimental
GB9702088D0 (en) * 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
DE69834556T2 (de) * 1997-04-15 2007-05-10 Pharmexa A/S Modifizierte humane TNFalpha-Moleküle, DNA, welche für derartige veränderte TNFalpha-Moleküle kodieren und Impfstoffe, die derartige veränderte TNFalpha-Moleküle und DNA enthalten
AU7345798A (en) * 1997-05-12 1998-12-08 Kennedy Institute Of Rheumatology, The Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Also Published As

Publication number Publication date
ATE488250T1 (de) 2010-12-15
JP2002538170A (ja) 2002-11-12
JP2011006464A (ja) 2011-01-13
US20060222646A1 (en) 2006-10-05
EP1159003A1 (en) 2001-12-05
EP1159003B1 (en) 2010-11-17
CA2364026C (en) 2012-08-21
WO2000051637A1 (en) 2000-09-08
AU3386100A (en) 2000-09-21
US20010021381A1 (en) 2001-09-13
US20020119152A1 (en) 2002-08-29
PT1159003E (pt) 2011-02-22
DE60045240D1 (de) 2010-12-30
AU756677B2 (en) 2003-01-23
CA2364026A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
DK1159003T3 (da) Anti-tnfalfa-antistoffer til terapi af steroid-resistent astma
CY1122092T1 (el) Ιατρικη χρηση ανθρωπινων αντισωματων υψηλης συγγενειας κατα του ανθρωπινου υποδοχεα il-4
DK0804236T3 (da) Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer
ATE549033T1 (de) Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
CY2012019I1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
ATE250439T1 (de) Dosierinhalator für salmeterol
DK1406656T3 (da) Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ATE515514T1 (de) Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
MY154009A (en) Anti-alpha v beta 6 antibodies
PT1315520E (pt) Utilizacao de anticorpos trifuncionais biespecificos e triespecificos para tratamento de ascites malignas
DK0841946T4 (da) Metoder til behandling af allergisk astma
DE60334076D1 (de) Monoklonaler anti-mensch-tenascin-Antikörper
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
CY1112673T1 (el) Φαινοξυ αιθερες αμινοξεων
WO2003063772A3 (en) Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
DE60331598D1 (de) Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
DK1476468T3 (da) Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
DK0840620T3 (da) IL-8-antagonister til behandling af astma
HK1154904A1 (zh) 天然 抗體及其抑制劑
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
BR0015872A (pt) Agentes antitrombóticos